Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PARP inhibitor 2X-121 · 1 trial · 1 indication
Overall tumor response according to RECIST
| Arm | Type | Description |
|---|---|---|
| PARP inhibitor 2X-121 | EXPERIMENTAL | 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients |
| Name | Type | Description |
|---|---|---|
| PARP inhibitor 2X-121 | DRUG | 600 mg PARP inhibitor 2X-121 as single daily oral agent in mBC patients |
Inclusion Criteria: * Signed informed consent form. * Age 18 years or older. * Histologically or cytological documented mBC (independent of hormone receptor, HER2 status and BRCA1 or 2 status) relapsed in 2 or more different prior therapies. * Measurable disease by CT scan or MRI. * With a drug res...
Top 20 of 93 competitors
PARP inhibitor 2X-121 is an investigational small molecule being studied for the treatment of metastatic breast cancer. It is a PARP inhibitor, a class of drugs that targets poly (ADP-ribose) polymerase enzymes involved in DNA repair. The drug is currently in Phase 2 clinical development.
PARP inhibitor 2X-121 targets poly (ADP-ribose) polymerase (PARP) enzymes, which play a role in DNA repair. By inhibiting these enzymes, the drug is designed to interfere with cancer cells' ability to repair DNA damage, potentially leading to cell death. It is being investigated for metastatic breast cancer.
PARP inhibitor 2X-121 is being developed by Allarity Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ALLR. The company is conducting clinical research on this investigational drug for the treatment of metastatic breast cancer.
PARP inhibitor 2X-121 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with metastatic breast cancer.
PARP inhibitor 2X-121 has one completed clinical trial, identified as NCT03562832. This Phase 2 study investigated the anti-tumour effect and tolerability of the drug in 20 patients with metastatic breast cancer in Denmark. The trial was uncontrolled, meaning there was no comparison group, and it enrolled adults aged 18 years and older.